Sotera Health Reports Strong Second-Quarter and First-Half 2026 Results, Raises Full-Year Financial Outlook
Sotera Health Company, a global provider of sterilization services, laboratory testing, and advisory solutions for the healthcare industry, has reported strong financial results for the second quarter and first half of 2026, highlighting broad-based growth across each of its three operating businesses. Supported by increased demand for its mission-critical healthcare services, favorable pricing, and operational execution, the company also raised its financial outlook for the remainder of the year.
Management stated that the quarter reflected continued momentum across Sterigenics, Nordion, and Nelson Labs, reinforcing the essential role the company’s services play in supporting medical device manufacturers, pharmaceutical companies, and healthcare organizations worldwide.
The improved financial performance, combined with a stronger balance sheet and enhanced liquidity position, has increased management’s confidence in the company’s long-term growth strategy.
Strong Quarterly Performance Across the Business
Sotera Health reported another quarter of healthy growth driven by solid execution across all operating segments.
The company indicated that its diversified portfolio continues to provide resilience despite ongoing inflationary pressures and evolving healthcare market conditions.
Revenue growth was supported by multiple factors, including:
- Favorable pricing initiatives
- Higher customer demand
- Improved product and service mix
- Continued operational efficiencies
- Positive foreign currency effects in several markets
Management emphasized that the combination of these drivers enabled the organization to generate consistent financial performance across its healthcare services platform.
CEO Highlights Essential Nature of the Business
Chief Executive Officer Alton Shader said the company’s second-quarter performance demonstrates both the strength of its business model and the critical role its services play throughout the global healthcare industry.
According to Shader, each of Sotera Health’s three operating businesses delivered high-single-digit or stronger growth during the quarter, reflecting disciplined execution and sustained customer demand.
Having recently joined the company, Shader noted that he has been particularly impressed by the expertise of Sotera Health employees, the confidence customers place in the organization, and the company’s leadership position in highly regulated healthcare markets.
He stated that these competitive advantages position the company to continue delivering reliable long-term growth while maintaining high standards of quality and customer service.
Company Raises Full-Year 2026 Outlook
Based on the strength of first-half financial performance and continued confidence in business conditions for the remainder of the year, Sotera Health announced an increase to its full-year 2026 financial outlook.
Management believes continued investments in people, facilities, operational capabilities, and customer relationships will support sustainable long-term expansion.
Shader explained that the company sees numerous opportunities to strengthen its market position while executing its long-term strategic priorities.
These initiatives include:
- Expanding customer partnerships
- Investing in operational capacity
- Enhancing laboratory capabilities
- Supporting innovation
- Improving service quality
- Strengthening healthcare industry relationships
The updated outlook reflects management’s confidence that current business momentum will continue throughout the second half of the year.
Sterigenics Delivers Strong Growth
Sterigenics, Sotera Health’s sterilization services business, generated another quarter of strong financial performance.
Second-quarter net revenue increased to $212 million, representing:
- 8.6% reported growth
- 7.0% constant-currency growth
Segment income reached $118 million, increasing 9.6% compared with the prior-year period.
Sterigenics provides sterilization services for medical devices, pharmaceuticals, laboratory products, food packaging, and other healthcare-related products requiring validated sterilization processes.
The business remains one of the world’s largest providers of outsourced sterilization services.
First-Half Sterigenics Performance
For the first six months of 2026, Sterigenics continued demonstrating consistent growth.
Results included:
- Net revenue: $398 million
- Revenue growth: 9.1% reported
- Constant-currency growth: 6.6%
- Segment income: $215 million
- Segment income growth: 9.6%
Management attributed this performance to continued demand from healthcare customers combined with effective pricing strategies and improved operational execution.
Drivers Behind Sterigenics Growth
According to the company, several factors contributed to Sterigenics’ strong quarterly results.
Revenue growth benefited from:
- Favorable pricing
- Increased service volumes
- Improved business mix
- Positive foreign currency translation
These positive factors also supported segment profitability.
Although inflation continued affecting operating costs, the business successfully offset much of that pressure through pricing and operational improvements.
Nordion Achieves Double-Digit Expansion
Nordion delivered the strongest percentage revenue growth among Sotera Health’s operating businesses during the second quarter.
Quarterly net revenue increased to $49 million, representing:
- 15.8% reported growth
- 16.7% constant-currency growth
Segment income reached $28 million, increasing 19.2% from the prior year.
Nordion specializes in the production and supply of medical isotopes and gamma technologies supporting healthcare, sterilization, and scientific applications worldwide.
Strong First-Half Results for Nordion
Performance remained equally strong during the first half of 2026.
For the six-month period, Nordion reported:
- Revenue: $91 million
- Revenue growth: 21.6%
- Constant-currency growth: 20.8%
- Segment income: $52 million
- Income growth: 26.4%
These results reflected continued operational momentum and favorable customer demand.
Timing of Cobalt-60 Harvests Supports Performance
Management indicated that Nordion’s growth was primarily driven by improvements in sales volume and product mix.
One important contributor was the timing of Cobalt-60 harvests.
Cobalt-60 plays a critical role in healthcare because it is widely used for:
- Medical device sterilization
- Cancer treatment technologies
- Radiation processing
- Scientific research
- Industrial applications
The timing of harvest schedules can significantly influence quarterly financial performance.
In addition to improved volumes, favorable pricing also contributed to revenue growth.
While foreign currency partially offset these gains, overall business performance remained exceptionally strong.
Nelson Labs Reports Continued Revenue Growth
Nelson Labs, Sotera Health’s laboratory testing and advisory services business, also reported positive quarterly results.
Second-quarter revenue increased to $61 million, representing:
- 6.3% reported growth
- 5.4% constant-currency growth
Segment income reached $20 million, reflecting a modest increase of 0.6% compared with the prior-year quarter.
Nelson Labs provides laboratory testing, microbiology services, analytical testing, consulting, and regulatory support for medical device manufacturers and healthcare companies worldwide.
First-Half Nelson Labs Results
During the first six months of 2026, Nelson Labs reported:
- Revenue: $113 million
- Revenue growth: 2.9%
- Constant-currency growth: 0.9%
- Segment income: $34 million
While revenue increased during the period, segment income declined 4.9%, reflecting higher operating expenses.
Higher Costs Affect Profit Margins
Management explained that Nelson Labs benefited from:
- Improved pricing
- Better customer demand
- Stronger service mix
- Favorable foreign exchange
However, increased operating costs limited profitability improvements.
Higher expenses affected segment income margins despite continued revenue expansion.
The company continues focusing on operational efficiency initiatives designed to improve long-term profitability within the laboratory testing business.
Supporting the Global Healthcare Industry
Sotera Health’s three operating businesses collectively provide essential services supporting virtually every stage of healthcare product development and delivery.
The company’s offerings include:
- Medical device sterilization
- Pharmaceutical sterilization
- Laboratory testing
- Product validation
- Regulatory consulting
- Radiation technologies
- Isotope production
Healthcare manufacturers rely on these services to help ensure products meet regulatory requirements while maintaining patient safety.
Because sterilization and laboratory testing are essential steps before many healthcare products reach patients, demand for these services tends to remain relatively stable.
Strong Balance Sheet Supports Future Growth
Alongside improved operating performance, Sotera Health continued strengthening its financial position.
As of June 30, 2026, the company reported:
- Total debt: $2.2 billion
- Cash and cash equivalents: $357 million
At the end of 2025, the company held:
- Total debt: $2.2 billion
- Cash and cash equivalents: $345 million
The increase in cash balances reflects continued improvement in liquidity while maintaining overall debt levels.
Net Leverage Ratio Reaches Long-Term Target
One of the company’s notable financial achievements during the quarter involved reducing leverage.
As of June 30, Sotera Health reported a Net Leverage Ratio of 3.0x.
This achievement places the company within its long-term target leverage range of:
- 2.0x to 3.0x
Reaching this target represents an important milestone in strengthening the balance sheet and improving financial flexibility.
Lower leverage also supports future investments while reducing financial risk.
Liquidity Position Continues Improving
Sotera Health also reported a stronger liquidity position.
Available liquidity increased to approximately $950 million as of June 30, 2026.
Importantly, the company had no outstanding borrowings under its $600 million revolving credit facility.
Maintaining substantial available liquidity provides flexibility to:
- Support future capital investments
- Fund strategic initiatives
- Pursue business expansion opportunities
- Manage economic uncertainty
- Maintain financial stability
The absence of revolving credit borrowings further strengthens the company’s financial profile.
Continued Focus on Long-Term Strategy
Management reiterated its commitment to executing the company’s long-term growth strategy.
Strategic priorities include:
- Expanding sterilization capacity
- Growing laboratory testing capabilities
- Investing in employees
- Enhancing operational efficiency
- Supporting healthcare innovation
- Building deeper customer relationships
These initiatives are intended to strengthen Sotera Health’s leadership position within highly regulated healthcare markets while supporting sustainable long-term financial performance.
Forward-Looking Financial Guidance
While raising its financial outlook, Sotera Health also noted that certain forward-looking non-GAAP financial measures cannot be reconciled with comparable GAAP measures on a prospective basis without unreasonable effort.
The company explained that future financial performance may be influenced by factors that cannot currently be predicted with sufficient accuracy.
These factors include:
- Regulatory developments
- Restructuring activities
- Fair value adjustments
- Other accounting items outside management’s direct control
As a result, management provides adjusted financial guidance while acknowledging the inherent uncertainty associated with future reconciling items.
Positioned for Continued Growth
Sotera Health’s second-quarter and first-half 2026 results demonstrate continued momentum across its diversified healthcare services platform. Strong revenue growth at Sterigenics, exceptional performance from Nordion, and steady expansion at Nelson Labs contributed to another quarter of solid financial execution, while improvements in liquidity and leverage strengthened the company’s overall financial position.
With increased confidence reflected in its higher full-year outlook, continued investments in operational capabilities, and growing demand for mission-critical sterilization, laboratory testing, and advisory services, Sotera Health believes it is well positioned to capitalize on long-term opportunities within the global healthcare industry. As healthcare manufacturers continue prioritizing product safety, regulatory compliance, and quality assurance, the company expects its specialized expertise and essential services to remain integral to supporting the development and delivery of healthcare products worldwide.
Source link: https://investors.soterahealth.com/
